Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Kayla A CarterInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore.
Susan TuddenhamDivision of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland.
Rebecca M BrotmanInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore.
University of Maryland, Baltimore · USJohns Hopkins University · US
Funding
TrainingU54EB007958 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI William Owen Osburn · 2007 to 2026
$34.6M
Cervicovaginal microbiome, mucosal immunity, and pathogen factors that contribute to spontaneous clearance of Chlamydia trachomatisR01AI167629 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROTMAN, REBECCA M., RAVEL, JACQUES · 2022 to 2025
$3.1M
Methods to Test the Role of Age-related Lifestyle and Vaginal Microenvironment Changes and the Prevention, Treatment, and Progression of Genitourinary Syndrome of MenopauseR01AG069915 · NIA · UNIVERSITY OF MARYLAND BALTIMORE · PI REBECCA M. BROTMAN, Michelle Denise Shardell · 2021 to 2026
$3.1M
Factors associated with Refractory and Early Recurrent Bacterial VaginosisR01AI182384 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Susan Anne Tuddenham · 2024 to 2026
$2.4M
Systems-Level Research in Microbial PathogenesisT32AI162579 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI NICHOLAS H CARBONETTI, Julie Dunning Hotopp · 2022 to 2026
$1.7M
Dysbiosis, Recurrent Bacterial Vaginosis and the Vaginal MicrobiomeK23AI125715 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TUDDENHAM, SUSAN ANNE · 2016 to 2020
$972k
Mechanisms of Successful Vaginal Estrogen Prophylaxis for Postmenopausal Women with Recurrent Urinary Tract Infections: Urogenital Microbiota and Host Immune ResponsesR01DK130856 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI HANDA, VICTORIA LYNN · 2022 to 2024
$969k
The vaginal microenvironment in asymptomatic versus symptomatic bacterial vaginosisR21AI168984 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TUDDENHAM, SUSAN ANNE · 2023 to 2024
$482k
Prospective contributions of the vaginal microbiome and immune milieu to spontaneous Chlamydia trachomatis clearanceF32AI181170 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CARTER, KAYLA A · 2024 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dequalinium Chloride-An Emerging Option in the Sparse Landscape of Bacterial Vaginosis Therapies. · full record | OpenQuestion